These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33441981)

  • 1. Novel Iodine nanoparticles target vascular mimicry in intracerebral triple negative human MDA-MB-231 breast tumors.
    Ridwan SM; Hainfeld JF; Ross V; Stanishevskiy Y; Smilowitz HM
    Sci Rep; 2021 Jan; 11(1):1203. PubMed ID: 33441981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distributions of intravenous injected iodine nanoparticles in orthotopic u87 human glioma xenografts over time and tumor therapy.
    Ridwan SM; El-Tayyeb F; Hainfeld JF; Smilowitz HM
    Nanomedicine (Lond); 2020 Oct; 15(24):2369-2383. PubMed ID: 32975163
    [No Abstract]   [Full Text] [Related]  

  • 4. Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice.
    Hainfeld JF; Ridwan SM; Stanishevskiy FY; Smilowitz HM
    Sci Rep; 2020 Sep; 10(1):15627. PubMed ID: 32973267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
    Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
    Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR anchored paclitaxel loaded PLGA nanoparticles for the treatment of triple negative breast cancer. In-vitro and in-vivo anticancer activities.
    Venugopal V; Krishnan S; Palanimuthu VR; Sankarankutty S; Kalaimani JK; Karupiah S; Kit NS; Hock TT
    PLoS One; 2018; 13(11):e0206109. PubMed ID: 30408068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LyP-1 Conjugated Nanoparticles for Magnetic Resonance Imaging of Triple Negative Breast Cancer.
    Abulrob A; Corluka S; Blasiak B; Gino Fallone B; Ponjevic D; Matyas J; Tomanek B
    Mol Imaging Biol; 2018 Jun; 20(3):428-435. PubMed ID: 29101636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
    Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo.
    Su M; Feng YJ; Yao LQ; Cheng MJ; Xu CJ; Huang Y; Zhao YQ; Jiang H
    Int J Gynecol Cancer; 2008; 18(3):476-86. PubMed ID: 17645504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.